Investigational ADC Ups Survival in Advanced Triple-Negative Breast Cancer

(MedPage Today) -- CHICAGO -- Treatment with investigational izalontamab brengitecan (iza-bren) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable locally advanced or metastatic triple...
Source
MedPage Today
Opens original article in a new tab



